Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women

Bone ◽  
2011 ◽  
Vol 48 ◽  
pp. S231
Author(s):  
S.J. Bae ◽  
Y.E. Chung ◽  
S.H. Lee ◽  
S.Y. Lee ◽  
S.Y. Kim ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Term Treatment ◽  
Long Term Treatment

Effect of long-term treatment with raloxifene on mammary density in postmenopausal women

2006 ◽  
Vol 13 (5) ◽  
pp. 787-792 ◽  
Author(s):  
Antonino Lasco ◽  
Agostino Gaudio ◽  
Elisa Morini ◽  
Nancy Morabito ◽  
Claudio Nicita-Mauro ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin

2011 ◽  
Vol 96 (5) ◽  
pp. 1197-1201 ◽  
Author(s):  
Esther S. Vollaard ◽  
André P. van Beek ◽  
Frederik A. J. Verburg ◽  
Annemieke Roos ◽  
Jolande A. Land
Keyword(s):  
Postmenopausal Women ◽  
Gnrh Agonist ◽  
Case Series ◽  
Term Treatment ◽  
Benign Tumors ◽  
Gnrh Agonists ◽  
Bilateral Oophorectomy ◽  
Increased Risk ◽  
Long Term Treatment

Context: The most frequent cause of virilization in postmenopausal women is excessive androgen production of ovarian origin. Bilateral oophorectomy is usually performed, even in cases of benign tumors or hyperthecosis. This is the first report of a case series of long-term GnRH-agonist treatment of hyperandrogenism in postmenopausal women. Objective: We present three women with postmenopausal hyperandrogenism of ovarian origin who were treated with GnRH agonists. Patients: We describe three cases of postmenopausal women with virilization and hyperandrogenism of presumed ovarian origin, all with slight enlargement of the ovaries but without visualization of a tumor, who had long-term treatment with GnRH agonists. No histological diagnosis was available, and therefore all patients received careful follow-up, including periodic testing of androgen levels and ovarian imaging by computed tomography scans. The three patients responded in different ways to treatment with GnRH agonists. Conclusions: Long-term GnRH agonist treatment is an acceptable choice for treatment of postmenopausal hyperandrogenism in patients where ovarian origin of androgen excess is ascertained, and especially in those patients who have an increased risk for surgery due to comorbidities or who are unwilling to undergo bilateral oophorectomy.

scholarly journals Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women

Diabetologia ◽  
2004 ◽  
Vol 47 (3) ◽  
pp. 571-574 ◽  
Author(s):  
A. Lasco ◽  
A. Gaudio ◽  
N. Morabito ◽  
M. Previti ◽  
A. Mileto ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Postmenopausal Women ◽  
Term Treatment ◽  
Long Term Treatment

Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women

2011 ◽  
Vol 23 (4) ◽  
pp. 1235-1243 ◽  
Author(s):  
Y. E. Chung ◽  
S. H. Lee ◽  
S.-Y. Lee ◽  
S.-Y. Kim ◽  
H.-H. Kim ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Term Treatment ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document